We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-9.4%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.21B
AUM Growth
-$432M
Cap. Flow
-$92.5M
Cap. Flow %
-4.18%
Top 10 Hldgs %
42.68%
Holding
227
New
13
Increased
52
Reduced
76
Closed
10

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$14.4M
2
CNC icon
Centene
CNC
+$8.41M
3
SNY icon
Sanofi
SNY
+$6.73M
4
LLY icon
Eli Lilly
LLY
+$6.66M
5
IQV icon
IQVIA
IQV
+$6.64M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$15.5M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$12.5M
3
JNJ icon
Johnson & Johnson
JNJ
+$11.1M
4
MDCO
Medicines Co
MDCO
+$10.3M
5
ELV icon
Elevance Health
ELV
+$9.94M

Sector Composition

Rank Sector Weight
1 Healthcare 95.66%
2 Real Estate 2.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
51
DELISTED
Blueprint Medicines
BPMC
$8.15M 0.37%
139,336
+22,411
+19% +$1.44M
OHI icon
52
Omega Healthcare
OHI
$14.6B
$8.13M 0.37%
306,433
+21,638
+8% +$821K
NVO
53
Novo Nordisk
NVO
$200B
$8.07M 0.36%
268,010
-174,718
-39% -$5.2M
MCK icon
54
McKesson
MCK
$99.9B
$8.05M 0.36%
59,525
-7,800
-12% -$1.14M
ZBH icon
55
Zimmer Biomet
ZBH
$19.1B
$7.9M 0.36%
80,513
+14,932
+23% +$1.96M
BAX icon
56
Baxter International
BAX
$14.1B
$7.89M 0.36%
97,183
-32,800
-25% -$2.83M
GSK icon
57
GSK
GSK
$104B
$7.84M 0.35%
165,494
-40,144
-20% -$2.14M
ASND icon
58
Ascendis Pharma A/S
ASND
$16.1B
$7.81M 0.35%
69,332
– –
MRNA icon
59
Moderna
MRNA
$23.2B
$7.61M 0.34%
+254,146
New +$5.85M
HCA icon
60
HCA Healthcare
HCA
$87.4B
$7.53M 0.34%
83,833
-12,000
-13% -$1.55M
NVCR icon
61
NovoCure
NVCR
$1.86B
$7.24M 0.33%
107,438
– –
MPT
62
Medical Properties Trust
MPT
$2.76B
$7.12M 0.32%
411,743
+37,454
+10% +$783K
TEVA icon
63
Teva Pharmaceuticals
TEVA
$40.1B
$7.06M 0.32%
785,851
– –
DOC
64
DELISTED
PHYSICIANS REALTY TRUST
DOC
$6.91M 0.31%
495,733
+38,977
+9% +$716K
KYNB
65
Kyntra Bio
KYNB
$28.5M
$6.75M 0.31%
7,771
– –
JAZZ icon
66
Jazz Pharmaceuticals
JAZZ
$16.6B
$6.73M 0.3%
67,456
-18,217
-21% -$2.36M
AGIO icon
67
Agios Pharmaceuticals
AGIO
$1.91B
$6.63M 0.3%
186,964
-29,444
-14% -$1.36M
IOVA icon
68
Iovance Biotherapeutics
IOVA
$1.99B
$6.62M 0.3%
221,073
-22,410
-9% -$594K
IMMU
69
DELISTED
Immunomedics Inc
IMMU
$6.57M 0.3%
487,103
– –
STRO icon
70
Sutro Biopharma
STRO
$431M
$6.54M 0.3%
64,127
– –
MRTX
71
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$6.06M 0.27%
78,784
+7,911
+11% +$709K
GBT
72
DELISTED
Global Blood Therapeutics, Inc.
GBT
$6.03M 0.27%
118,083
-29,085
-20% -$1.95M
UTHR icon
73
United Therapeutics
UTHR
$22B
$6.02M 0.27%
63,513
+9,419
+17% +$895K
ARGX icon
74
argenx
ARGX
$54.2B
$5.92M 0.27%
44,977
– –
BCEL
75
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$5.83M 0.26%
352,424
-172,472
-33% -$3.13M
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, Tekla Capital Management held 227 positions worth $2.21B, down 16% from $2.64B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Tekla Capital Management withdrew a net $92.5M in Q1 2020, closing 10 positions and reducing 76 holdings. Its most notable exit was Medicines Co, an estimated $10.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Real Estate.

Against the trend, Tekla Capital Management opened a new position in Moderna worth $7.61M.

  • Tekla Capital Management's largest Q1 2020 buy was Moderna: 254,146 shares worth $7.61M.
  • Tekla Capital Management added most to Biogen in Q1 2020, an estimated $14.4M increase.
  • Tekla Capital Management's biggest Q1 2020 reduction was Merck, cutting an estimated $15.5M.
  • Tekla Capital Management fully exited Medicines Co in Q1 2020, selling an estimated $10.3M.
  • Tekla Capital Management's ten largest holdings make up 43% of its $2.21B portfolio in Q1 2020.
  • Tekla Capital Management opened 13 new positions and closed 10 in Q1 2020.
  • Tekla Capital Management's portfolio value fell 16% quarter-over-quarter to $2.21B.

Based on Tekla Capital Management's 13F filing for Q1 2020, filed 14 May 2020.